CHRS - コヒ―ラス・バイオサイエンシズ （Coherus BioSciences Inc.）

Coherus BioSciences <>, a biotech focused on biosimilars and immuno-oncology products, is trading higher on Tuesday after indicating its long-term prospects with plans to launch…

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS ) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). As of October 31, 2021, at the final analysis, a significant improvement in … Full story available on Benzinga.com

Coherus BioSciences (CHRS) appointed Rosh Dias as chief medical officer ((CMO)).Dias joins Coherus most recently from Spruce Biosciences, where he was the CMO

Coherus BioSciences (CHRS) and partner Shanghai Junshi BioSciences said that their non-small cell lung cancer therapy toripalimab led to an improvement in progression-free survival.

Coherus BioSciences (CHRS) and Shanghai Junshi Biosciences (SHJBF) esophageal cancer candidate toripalimab met co-primary endpoints in a phase 3 trial.

In last trading session, Coherus BioSciences Inc. (NASDAQ:CHRS) saw 0.65 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $11.73 trading at $0.27 or 2.36% at ring of the bell on the day assigns it a market valuation of $939.46M. That closing price of CHRS’s stock is … Coherus BioSciences Inc. (NASDAQ:CHRS) Is 10.23% Above Its 52-Week Low, But How Long Will It Remain So? Read More »

Coherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on Benzinga.com

CHRS earnings call for the period ending December 31, 2021.

Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the scope of particular product with respect to the driving factors and restraints

REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus management team will host a conference call and webcast to discuss financial results and provide a general business update.

This report studies the Adalimumab Biosimilar Sales Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Adalimumab Biosimilar Sales market segmented by company, []

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) (announced a collaboration with Biovac to manufacture COVID-19 shots in South Africa) Bristol-Myers Squibb Company (NYSE: BMY ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Century Therapeutics, Inc. (NASDAQ: IPSC ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced positive data for pipeline asset in periodontal disease) Eli Lilly and Company (NYSE: LLY ) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) (reacted to its second-quarter results) Novo Nordisk A/S (NYSE: NVO ) PLx Pharma Inc. (NASDAQ: PLXP ) ResMed Inc. (NYSE: RMD ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) 23andMe Holding Co.

This report studies the Behcet Disease Treatment Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Behcet Disease Treatment market segmented by company, []